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harvests. In addition, this prediction model will enable us to
identify additional genetic determinants for collection efﬁ-
ciency in bone marrow.439
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Background: Despite the progress of antiviral therapy in
recent years, CMV infection continues to be a major
complication after allogeneic hematopoietic cell trans-
plantation (HCT). We aimed to study the risk factors for ﬁrst
and subsequent CMV infections among patients who are
CMV seropositive.
Methods: we analyzed all sequential CMV seropositive pa-
tients that were given allogeneic HCT in a single center. We
tested the impact of a variety of patients and trans-
plantation’s characteristics on both ﬁrst and subsequent
CMV reactivations. Signiﬁcant factors identiﬁed on multi-
variate analyses were entered intomodels to predict ﬁrst and
subsequent CMV reactivation.
Results: Between May 2007 and December 2012, 121 CMV
seropositive patients were given allograft. Multivariate
model identiﬁed myeloablative preparative regimen
(HR¼4.297, p¼.033) and acute GVHD prior to infection
(HR¼5.091, p¼.021) as risk factors for ﬁrst CMV infection.
The cumulative incidences of ﬁrst CMV infection for patients
with 0, 1 and 2 risk factors were 52%, 71% and 91%, respec-
tively, Figure. Receiver operating curves for the model
showed for one risk factor a sensitivity of 84% and speciﬁcity
of 34% and for 2 risk factors 41% and 91%, respectively.
Multivariate analysis identiﬁed the diagnosis of lymphoma/
myeloma (HR¼3.5, p¼.049) and GVHD (HR¼1.280, p¼.045)
as risk factors for subsequent CMV infection. High graft CD3
stem cell dose was protective (HR¼0.543, p¼.056). The cu-
mulative incidences for subsequent CMV reactivation in pa-
tients with 0, 1, and 2-3 risk factors were 11%, 43% and 77%,
respectively. Receiver operating curves for the model
showed for one risk factor a sensitivity of 67% and speciﬁcity
of 90% and for more than 2 risk factors 93% and 47%,
respectively.Figure.Conclusions: In CMV seropositive patients, myeloablative
conditioning and acute GVHD are risk factors for ﬁrst CMV
infection and lymphoma/myeloma, ongoing GVHD and low
CD3 graft content are risk factors for a subsequent in-
fection.440
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UCBT has high early transplant-related mortality. We
explored the feasibility of using related, mismatched, and
unmanipulated bone marrow as third party donor graft with
the addition of post-transplant cyclophosphamide (PtCy) for
unrelated single unit UCBT (dual transplants). Our aimwas to
decrease UCBT early mortality without increasing aGvHD.
We compared 16 cases of dual transplant (09/2012-08/14,
center 1) with two single UCBT historical groups; one with
PtCy (20 cases, 07/2010-08/12, center 1 & 2), and a 2nd
without PtCy (31 cases, 03/2010-07/12, center 2). We did not
include Fanconi and dyskeratosis congenita patients. The
main features of this dual platform were; 1. Pre-transplant
rATG (7 mg/kg/total dose) with Rituximab (100 mg/m2/total
dose), 2. Related bone marrow graft stimulated with 3 days
G-CSF and 3. PtCy on days +3 and +4 (100 mg/kg/total dose).
We used this core for bothmyeloablative (59%) and RIC UCBT.
In the ﬁrst 11 cases, CSA and MMF were started at day +5. In
the other 6 patients, we used sirolimus before transplant
(day -6) and MMF (day +5). To estimate adjusted hazards
rates (HR) by transplant group we carried out Cox’s multi-
variate regression models clustered by transplant year.
Covariates included in the models were: age, sex, RIC, HLA
match, CMV receptor status, pre-freezing total nucleated
cells (TNC), CD34, female:male receptor:donor mismatch.
Receptors in the dual group were older (median age (yrs)
12.1 vs 6.0 vs 6.7; P<0.01). Median CB TNC and CD34 cells
infused for dual, with and without PtCy were 5.7 vs 6.7 vs
5.4x107/kg (P¼0.08), and 2.2 vs 2.7 vs 2.7x105/kg (P¼0.45),
respectively. Dual, PtCy, and non-PtCy groupsmedian time to
neutrophil and platelet engraftment was 18.5 vs 25 vs 17
days (P¼0.07), and 19 vs 40.5 vs 33 (P¼0.01), respectively.
Grades II-IV aGvHD for each group was 47%, 31%, and 56%
(P¼0.30). There were no cases of grade IV aGvHD in the dual
or the PtCy group. Acute leukemia 12 months cumulative
relapse was 6% for dual compared with the other 2 groups
(32% and 33%, P¼0.12). Cumulative 100-daymortality was 7%
for dual compared with 23% and 28% for the other two co-
horts (P¼0.1). Using the non-PtCy cohort as referent, 100-day
mortality HR was 0.2 (95%CI: 0.1, 0.6) for dual and 0.9 (95%CI:
0.2, 5.2) for the PtCy group. One-year HR was 0.6 (95%CI: 0.3,
1.5) for dual, and 0.9 (95%CI: 0.3, 2.9) for the PtCy group.
Overall, PtCy-dual transplant approach decreases 100-day
